Recent Updates
Recently added Catalysts
CORT Positive Sentiment

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study

Monday, June 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The MOMENTUM Study results were presented at the Endocrine Society Annual Meeting, highlighting the characterization of individuals with resistant hypertension and their cortisol levels post-dexamethasone suppression test. The findings may provide valuable insights into managing this condition. The study emphasizes the importance of cortisol measurements in understanding hypertension resistance.
Price reaction · baseline $83.16 (2026-06-15T17:00:00.000Z) · hit during market hours · 5 other CORT headline(s) in the window, move may be shared
day 0 close · peak
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Presentation at a prominent scientific meeting.
  • Focus on a significant health issue: resistant hypertension.
  • Potential for new insights into cortisol levels and hypertension.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+283%
120-day peak, hindsight
Typical move
4.8%
average across 6 past catalysts
Lead asset
mifepristone+ fluvastatin
Phase 1 · Healthy Subjects

Full Press Release Details

Presented : Endocrine Society (ENDO) Annual Meeting, 15 June 2026, Chicago, IL
Presenter : Bradley Eilerman, MD, MHI
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study appeared first on Corcept Therapeutics .

Frequently Asked Questions

What was presented at the ENDO Annual Meeting?

The MOMENTUM Study results on resistant hypertension and cortisol levels were presented.

Who presented the MOMENTUM Study findings?

Dr. Bradley Eilerman, MD, MHI, presented the findings.

What is the focus of the MOMENTUM Study?

The study focuses on individuals with resistant hypertension and their cortisol levels.

When was the ENDO Annual Meeting held?

The meeting took place on 15 June 2026 in Chicago, IL.

ShareAdd on Google
Tags: CORT Viatris Investor Conferences Healthcare resistant hypertension MOMENTUM Study cortisol levels ENDO 2026
Last updated: Jun 15, 2026

Biotech snapshot

Cash runway
$545M liquidity · $0M/mo burn
Low dilution risk
Lead asset
mifepristone+ fluvastatinPhase 1
Healthy Subjects →

Catalyst track record

+283%
best trade around CORT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CORT.

See every catalyst's timing & PoA →